MANNKIND CORP (MNKD) Stock Fundamental Analysis
NASDAQ:MNKD - US56400P7069 - Common Stock
5.57 USD
+0.06 (+1.09%)
5.57 USD
0 (0%)
Overall MNKD gets a fundamental rating of 5 out of 10. We evaluated MNKD against 541 industry peers in the Biotechnology industry. Both the profitability and the financial health of MNKD get a neutral evaluation. Nothing too spectacular is happening here. MNKD is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
MNKD had a positive operating cash flow in the past year.
In the past 5 years MNKD reported 4 times negative net income.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
MNKD's Return On Assets of 7.85% is amongst the best of the industry. MNKD outperforms 92.42% of its industry peers.
MNKD's Return On Invested Capital of 21.43% is amongst the best of the industry. MNKD outperforms 97.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.85% | ||
| ROE | N/A | ||
| ROIC | 21.43% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MNKD's Profit Margin of 10.71% is amongst the best of the industry. MNKD outperforms 92.24% of its industry peers.
MNKD's Operating Margin of 26.40% is amongst the best of the industry. MNKD outperforms 95.75% of its industry peers.
The Gross Margin of MNKD (77.36%) is better than 83.36% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.4% | ||
| PM (TTM) | 10.71% | ||
| GM | 77.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
The number of shares outstanding for MNKD has been increased compared to 1 year ago.
The number of shares outstanding for MNKD has been increased compared to 5 years ago.
Compared to 1 year ago, MNKD has an improved debt to assets ratio.
2.2 Solvency
MNKD has an Altman-Z score of -6.81. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
MNKD has a Altman-Z score of -6.81. This is in the lower half of the industry: MNKD underperforms 66.36% of its industry peers.
MNKD has a debt to FCF ratio of 10.09. This is a negative value and a sign of low solvency as MNKD would need 10.09 years to pay back of all of its debts.
The Debt to FCF ratio of MNKD (10.09) is better than 91.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 10.09 | ||
| Altman-Z | -6.81 |
ROIC/WACC2.27
WACC9.46%
2.3 Liquidity
MNKD has a Current Ratio of 2.50. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a Current ratio of 2.50. This is in the lower half of the industry: MNKD underperforms 69.32% of its industry peers.
A Quick Ratio of 2.24 indicates that MNKD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.24, MNKD is doing worse than 70.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.24 |
3. Growth
3.1 Past
MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.00%, which is quite impressive.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 21.46%.
Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)21.46%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
3.2 Future
Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 42.76% on average per year.
Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 13.53% on average per year.
EPS Next Y69.4%
EPS Next 2Y38.95%
EPS Next 3Y48.47%
EPS Next 5Y42.76%
Revenue Next Year13.93%
Revenue Next 2Y13.37%
Revenue Next 3Y13.95%
Revenue Next 5Y13.53%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 61.89 indicates a quite expensive valuation of MNKD.
Based on the Price/Earnings ratio, MNKD is valued cheaply inside the industry as 91.13% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.07, MNKD is valued quite expensively.
With a Price/Forward Earnings ratio of 36.06, MNKD can be considered very expensive at the moment.
90.57% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.59, MNKD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.89 | ||
| Fwd PE | 36.06 |
4.2 Price Multiples
93.90% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MNKD is valued cheaper than 92.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.37 | ||
| EV/EBITDA | 18.65 |
4.3 Compensation for Growth
MNKD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 48.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y38.95%
EPS Next 3Y48.47%
5. Dividend
5.1 Amount
No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.57
+0.06 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.79%
Inst Owner Change-3.76%
Ins Owners1.54%
Ins Owner Change2.43%
Market Cap1.71B
Analysts84.62
Price Target9.91 (77.92%)
Short Float %6.92%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.44%
Min EPS beat(2)-100%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-40.95%
Min EPS beat(4)-100%
Max EPS beat(4)-10.87%
EPS beat(8)2
Avg EPS beat(8)-37.57%
EPS beat(12)5
Avg EPS beat(12)-17.45%
EPS beat(16)6
Avg EPS beat(16)-13.49%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-2.76%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)0.9%
Revenue beat(8)5
Avg Revenue beat(8)1.49%
Revenue beat(12)8
Avg Revenue beat(12)4.61%
Revenue beat(16)11
Avg Revenue beat(16)4.15%
PT rev (1m)6.46%
PT rev (3m)-5.56%
EPS NQ rev (1m)-53.12%
EPS NQ rev (3m)-57.14%
EPS NY rev (1m)-26.87%
EPS NY rev (3m)-26.19%
Revenue NQ rev (1m)1.13%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.89 | ||
| Fwd PE | 36.06 | ||
| P/S | 5.66 | ||
| P/FCF | 59.37 | ||
| P/OCF | 49.47 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.65 |
EPS(TTM)0.09
EY1.62%
EPS(NY)0.15
Fwd EY2.77%
FCF(TTM)0.09
FCFY1.68%
OCF(TTM)0.11
OCFY2.02%
SpS0.98
BVpS-0.18
TBVpS-0.2
PEG (NY)0.89
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.85% | ||
| ROE | N/A | ||
| ROCE | 26.57% | ||
| ROIC | 21.43% | ||
| ROICexc | 45.85% | ||
| ROICexgc | 48.02% | ||
| OM | 26.4% | ||
| PM (TTM) | 10.71% | ||
| GM | 77.36% | ||
| FCFM | 9.54% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 10.09 | ||
| Debt/EBITDA | 3.03 | ||
| Cap/Depr | 67.99% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 5.4 | ||
| Cash Conversion | 39.2% | ||
| Profit Quality | 89.07% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.24 | ||
| Altman-Z | -6.81 |
F-Score8
WACC9.46%
ROIC/WACC2.27
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y69.4%
EPS Next 2Y38.95%
EPS Next 3Y48.47%
EPS Next 5Y42.76%
Revenue 1Y (TTM)21.46%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
Revenue Next Year13.93%
Revenue Next 2Y13.37%
Revenue Next 3Y13.95%
Revenue Next 5Y13.53%
EBIT growth 1Y74.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y150.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y229.39%
OCF growth 3YN/A
OCF growth 5YN/A